Cargando…

Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment

Autoimmune rheumatic diseases (AIRDs) constitute a set of connective tissue disorders and dysfunctions with akin clinical manifestations and autoantibody responses. AIRD treatment is based on a comprehensive approach, with the primary aim being achieving and attaining disease remission, through the...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexandropoulou, Ioanna, Grammatikopoulou, Maria G., Gkouskou, Kalliopi K., Pritsa, Agathi A., Vassilakou, Tonia, Rigopoulou, Eirini, Lindqvist, Helen M., Bogdanos, Dimitrios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824311/
https://www.ncbi.nlm.nih.gov/pubmed/36615886
http://dx.doi.org/10.3390/nu15010229
_version_ 1784866378479566848
author Alexandropoulou, Ioanna
Grammatikopoulou, Maria G.
Gkouskou, Kalliopi K.
Pritsa, Agathi A.
Vassilakou, Tonia
Rigopoulou, Eirini
Lindqvist, Helen M.
Bogdanos, Dimitrios P.
author_facet Alexandropoulou, Ioanna
Grammatikopoulou, Maria G.
Gkouskou, Kalliopi K.
Pritsa, Agathi A.
Vassilakou, Tonia
Rigopoulou, Eirini
Lindqvist, Helen M.
Bogdanos, Dimitrios P.
author_sort Alexandropoulou, Ioanna
collection PubMed
description Autoimmune rheumatic diseases (AIRDs) constitute a set of connective tissue disorders and dysfunctions with akin clinical manifestations and autoantibody responses. AIRD treatment is based on a comprehensive approach, with the primary aim being achieving and attaining disease remission, through the control of inflammation. AIRD therapies have a low target specificity, and this usually propels metabolic disturbances, dyslipidemias and increased cardiovascular risk. Ceramides are implicated in inflammation through several different pathways, many of which sometimes intersect. They serve as signaling molecules for apoptosis, altering immune response and driving endothelial dysfunction and as regulators in the production of other molecules, including sphingosine 1-phosphate (S1P) and ceramide 1-phosphate (C1P). With lipid metabolism being severely altered in AIRD pathology, several studies show that the concentration and variety of ceramides in human tissues is altered in patients with rheumatic diseases compared to controls. As a result, many in vitro and some in vivo (animal) studies research the potential use of ceramides as therapeutic targets in rheumatoid arthritis (RA), ankylosing spondylitis, systemic lupus erythematosus, fibromyalgia syndrome, primary Sjögren’s syndrome, systemic sclerosis, myositis, systemic vasculitis and psoriatic arthritis. Furthermore, the majority of ceramide synthesis is diet-centric and, as a result, dietary interventions may alter ceramide concentrations in the blood and affect health. Subsequently, more recently several clinical trials evaluated the possibility of distinct dietary patterns and nutrients to act as anti-ceramide regimes in humans. With nutrition being an important component of AIRD-related complications, the present review details the evidence regarding ceramide levels in patients with AIRDs, the results of anti-ceramide treatments and discusses the possibility of using medical nutritional therapy as a complementary anti-ceramide treatment in rheumatic disease.
format Online
Article
Text
id pubmed-9824311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98243112023-01-08 Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment Alexandropoulou, Ioanna Grammatikopoulou, Maria G. Gkouskou, Kalliopi K. Pritsa, Agathi A. Vassilakou, Tonia Rigopoulou, Eirini Lindqvist, Helen M. Bogdanos, Dimitrios P. Nutrients Review Autoimmune rheumatic diseases (AIRDs) constitute a set of connective tissue disorders and dysfunctions with akin clinical manifestations and autoantibody responses. AIRD treatment is based on a comprehensive approach, with the primary aim being achieving and attaining disease remission, through the control of inflammation. AIRD therapies have a low target specificity, and this usually propels metabolic disturbances, dyslipidemias and increased cardiovascular risk. Ceramides are implicated in inflammation through several different pathways, many of which sometimes intersect. They serve as signaling molecules for apoptosis, altering immune response and driving endothelial dysfunction and as regulators in the production of other molecules, including sphingosine 1-phosphate (S1P) and ceramide 1-phosphate (C1P). With lipid metabolism being severely altered in AIRD pathology, several studies show that the concentration and variety of ceramides in human tissues is altered in patients with rheumatic diseases compared to controls. As a result, many in vitro and some in vivo (animal) studies research the potential use of ceramides as therapeutic targets in rheumatoid arthritis (RA), ankylosing spondylitis, systemic lupus erythematosus, fibromyalgia syndrome, primary Sjögren’s syndrome, systemic sclerosis, myositis, systemic vasculitis and psoriatic arthritis. Furthermore, the majority of ceramide synthesis is diet-centric and, as a result, dietary interventions may alter ceramide concentrations in the blood and affect health. Subsequently, more recently several clinical trials evaluated the possibility of distinct dietary patterns and nutrients to act as anti-ceramide regimes in humans. With nutrition being an important component of AIRD-related complications, the present review details the evidence regarding ceramide levels in patients with AIRDs, the results of anti-ceramide treatments and discusses the possibility of using medical nutritional therapy as a complementary anti-ceramide treatment in rheumatic disease. MDPI 2023-01-02 /pmc/articles/PMC9824311/ /pubmed/36615886 http://dx.doi.org/10.3390/nu15010229 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Alexandropoulou, Ioanna
Grammatikopoulou, Maria G.
Gkouskou, Kalliopi K.
Pritsa, Agathi A.
Vassilakou, Tonia
Rigopoulou, Eirini
Lindqvist, Helen M.
Bogdanos, Dimitrios P.
Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment
title Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment
title_full Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment
title_fullStr Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment
title_full_unstemmed Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment
title_short Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment
title_sort ceramides in autoimmune rheumatic diseases: existing evidence and therapeutic considerations for diet as an anticeramide treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824311/
https://www.ncbi.nlm.nih.gov/pubmed/36615886
http://dx.doi.org/10.3390/nu15010229
work_keys_str_mv AT alexandropoulouioanna ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT grammatikopouloumariag ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT gkouskoukalliopik ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT pritsaagathia ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT vassilakoutonia ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT rigopouloueirini ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT lindqvisthelenm ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment
AT bogdanosdimitriosp ceramidesinautoimmunerheumaticdiseasesexistingevidenceandtherapeuticconsiderationsfordietasananticeramidetreatment